SEC Form 4 Ingestion•Corporate Insider Trade•Filed: 2026-08-03
👔
HERON THERAPEUTICS, INC. /DE/
@HRTX_InsiderForm 4 Filing: Hensley Mark Earl Exercises Options for shares of $HRTX
OPTION EXERCISE
⚡ MATERIALITY: 2/10
corporate issuer
HERON THERAPEUTICS, INC. /DE/
Ticker: $HRTX
Transaction Value
N/A (Non-Open-Market)
Price/Share: $0.00 (Non-Open-Market)
transaction date
2026-07-31
Shares: 11,769
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Hensley Mark Earl, holds the title of Chief Operating Officer at HERON THERAPEUTICS, INC. /DE/.
On 2026-07-31, the insider transacted 11,769 shares.This transaction is a non-open-market event (such as a stock grant or option exercise) with a reported price per share of $0.00.
Executive Summary Summary
Hensley Mark Earl (Chief Operating Officer) exercised options for $0 of $HRTX
Post-Transaction Position: 148,539 shares
SEC Accession No: 0001193125-26-329848 (CIK: 2065816)
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.